Monetary Costs of Agitation in Older Adults with Alzheimer's Disease in the UK: Prospective Cohort Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2015 Mar 15

PMID 25770235

Citations 25

Authors

Stephen Morris

Nishma Patel

Gianluca Baio

Lynsey Kelly

Elanor Lewis-Holmes

Rumana Z Omar

Cornelius Katona

Claudia Cooper

Gill Livingston

Affiliations

Soon will be listed here.

Abstract

Objective: While nearly half of all people with Alzheimer's disease (AD) have agitation symptoms every month, little is known about the costs of agitation in AD. We calculated the monetary costs associated with agitation in older adults with AD in the UK from a National Health Service and personal social services perspective.

Design: Prospective cohort study.

Setting: London and the South East Region of the UK (LASER-AD study).

Participants: 224 people with AD recruited between July 2002 and January 2003 and followed up for 54 months.

Primary And Secondary Outcome Measures: The primary outcome was health and social care costs, including accommodation costs and costs of contacts with health and social care services. Agitation was assessed using the Neuropsychiatric Inventory (NPI) agitation score.

Results: After adjustment, health and social care costs varied significantly by agitation, from £29,000 over a 1 year period with no agitation symptoms (NPI agitation score=0) to £57,000 at the most severe levels of agitation (NPI agitation score=12; p=0.01). The mean excess cost associated with agitation per person with AD was £4091 a year, accounting for 12% of the health and social care costs of AD in our data, and equating to £2 billion a year across all people with AD in the UK.

Conclusions: Agitation in people with AD represents a substantial monetary burden over and above the costs associated with cognitive impairment.

Citing Articles

Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia.

Teigland C, Pulungan Z, Bruhn D, Hwang S J Health Econ Outcomes Res. 2024; 11(2):118-124.

PMID: 39507604 PMC: 11539929. DOI: 10.36469/001c.124455.

Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.

Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M Alzheimers Dement. 2024; 20(11):8002-8011.

PMID: 39369280 PMC: 11567808. DOI: 10.1002/alz.14282.

Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.

Lu W, Liu F, Zhang Y, He X, Hu Y, Xu H BMJ Ment Health. 2024; 27(1.

PMID: 39079887 PMC: 11293415. DOI: 10.1136/bmjment-2024-301019.

A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.

Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L Health Technol Assess. 2023; 27(23):1-108.

PMID: 37929672 PMC: 10641860. DOI: 10.3310/VPDT7105.

The Costs of Dementia in Europe: An Updated Review and Meta-analysis.

Jonsson L, Tate A, Frisell O, Wimo A Pharmacoeconomics. 2022; 41(1):59-75.

PMID: 36376775 DOI: 10.1007/s40273-022-01212-z.

References

Cummings J . The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48(5 Suppl 6):S10-6. DOI: 10.1212/wnl.48.5_suppl_6.10s. View

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

Rowen D, Mulhern B, Banerjee S, van Hout B, Young T, Knapp M . Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. Value Health. 2012; 15(2):346-56. DOI: 10.1016/j.jval.2011.10.016. View

Schneider L, Tariot P, Lyketsos C, Dagerman K, Davis K, Davis S . National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9(4):346-60. View

Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N . A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. 2014; 18(39):1-226, v-vi. PMC: 4781145. DOI: 10.3310/hta18390. View

Ryu S, Katona C, Rive B, Livingston G . Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry. 2005; 13(11):976-83. DOI: 10.1176/appi.ajgp.13.11.976. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G . Relationship of vascular risk to the progression of Alzheimer disease. Neurology. 2006; 67(8):1357-62. DOI: 10.1212/01.wnl.0000240129.46080.53. View

Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N . Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014; 205(6):436-42. DOI: 10.1192/bjp.bp.113.141119. View

10.

Lyketsos C, Lopez O, Jones B, Fitzpatrick A, Breitner J, DeKosky S . Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002; 288(12):1475-83. DOI: 10.1001/jama.288.12.1475. View

11.

Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B . Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011; 7(3):318-27. DOI: 10.1016/j.jalz.2010.09.001. View

12.

Paradise M, Walker Z, Cooper C, Blizard R, Regan C, Katona C . Prediction of survival in Alzheimer's disease--the LASER-AD longitudinal study. Int J Geriatr Psychiatry. 2009; 24(7):739-47. DOI: 10.1002/gps.2190. View

13.

Murman D, Chen Q, Powell M, Kuo S, Bradley C, Colenda C . The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002; 59(11):1721-9. DOI: 10.1212/01.wnl.0000036904.73393.e4. View

14.

Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G . Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006; 21(5):449-59. DOI: 10.1002/gps.1489. View

15.

Barber J, Thompson S . Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004; 9(4):197-204. DOI: 10.1258/1355819042250249. View

16.

Selbaek G, Kirkevold O, Engedal K . The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry. 2006; 22(9):843-9. DOI: 10.1002/gps.1749. View

17.

Mahoney R, Regan C, Katona C, Livingston G . Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. Am J Geriatr Psychiatry. 2005; 13(9):795-801. DOI: 10.1176/appi.ajgp.13.9.795. View

18.

Mulhern B, Smith S, Rowen D, Brazier J, Knapp M, Lamping D . Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis. Value Health. 2012; 15(2):323-33. DOI: 10.1016/j.jval.2011.09.006. View

19.

Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B . Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007; 64(12):1755-61. PMC: 2690610. DOI: 10.1001/archneur.64.12.1755. View

20.

Martinez C, Jones R, Rietbrock S . Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013; 3(1). PMC: 3549220. DOI: 10.1136/bmjopen-2012-002080. View